Produced by 
OCT 17, 2017 08:00 AM PDT
WEBINAR: Transcriptomics to decipher the pathobiology of drug resistance and enable targeted therapeutics
SPONSORED BY: Thermo Fisher Scientific - Applied Biosystems
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
8 32 3147

Speakers:
  • Assistant Research Professor, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine
    Biography
      Dr. Yesim Gökmen-Polar is an Assistant Research Professor in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine. Her research interests are centered on the identification of novel therapeutic targets in breast and thymic cancers resistant to standard of care therapy. She has approximately 50 publications mainly in the field of cancer biology. Her specific expertise is in development of novel therapeutic targets (i.e. targeting EphA2 receptor tyrosine kinase, protein kinase C beta, anti-tubulins and TORC1/2) in colon, breast cancer and thymic malignancies. Her lab developed and characterized a novel human thymoma model, designated as IU-TAB-1, which was derived from a patient with the stage II thymoma (WHO type A/B). Dr. Gökmen-Polar's current research uses next generation sequencing (NGS), next generation microarrays such as Clariom D Human Transcriptome Analysis, and preclinical models to understand the transcriptional regulation/mechanisms of resistance and develop novel targeted therapies. The ultimate goal of her research is to prevent development of recurrences and improve the quality of life for patients.

    Abstract:

    DATE: October 17, 2017
    TIME: 08:00am PDT, 11:00am EDT

    Researching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an individual basis. Computational biology tools combined with transcriptome analysis allow the characterization of differential gene expression signatures in response to treatment in resistant vs non-resistant human-derived cancer cells. Many biomarkers including non-coding RNAs and alternatively spliced variants have been associated with tumor pathogenesis or drug resistance. These biomarkers represent candidates to help elucidate the biology of diseases, to identify the mechanisms for drug resistance, and to design better targeted therapies for precision medicine.

     

    In this webinar, the speaker will:

    • Explain the importance of non-coding RNAs and alternative splicing in cancer biology
    • Describe transcriptomics workflows to identify biomarkers and drug resistance mechanisms
    • Share applications in breast and thymic cancer research

     

    For Research Use Only. Not for use in diagnostic procedures.


    Show Resources